Clinical trials: End of Life Patients
Depression, End Stage Renal Disease
CBT to Treat Depression in Renal Patients
The purpose of this study is to determine whether Cognitive Behavioral Therapy is effective in the treatment of depression in patients with end-stage renal disease in hemodialysis therapy
- Trial name
- CBTRPat (NCT00530296)
- Testing
- Cognitive Behavioral Therapy
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of São Paulo
End of Life Care, Liver Cirrhosis
Palliative Care for Patients With Liver Cirrhosis
Background: Patients with liver cirrhosis rarely receive palliative care although the Danish Health Authorities and WHO recommend it.
- Conditions
- End of Life Care, Liver Cirrhosis, Nurse-Patient Relations, Quality of Life
- Trial name
- LiverCare (NCT05431946)
- Testing
- Advance Care Planning and the consequent actions
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Trauma
Accuracy of the New Injury Severity Score in Evaluating Patients With Blunt Trauma
The goal of this prospective observational study is to evaluate the predictive utility of the New Injury Severity Score (NISS) in determining mortality outcomes among blunt trauma patients admitted to the Emergency Department of…
- Trial name
- NISS/ER (NCT06711276)
- Where
- Iraq
- Volunteers
- 210 people
- Sponsor
- Al-Nahrain University
Non-small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung…
- Trial name
- NCT02039674
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, Cardiac Death
BioFreedom QCA Study in CAD Patients
This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.
- Conditions
- Coronary Artery Disease, Cardiac Death, Myocardial Infarction
- Trial name
- BioFreedomQCA (NCT03307213)
- Testing
- BioFreedom™ CoCr Biolimus A9™ stent, BioFreedom™ SS Biolimus A9™ stent
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 200 people
- Sponsor
- Biosensors Europe SA
Sudden Cardiac Death, End Stage Renal Disease
T-Wave Alternans in Dialysis Patients
Sudden cardiac death due to arrhythmia is the leading cause of death in end-stage renal disease (ESRD) patients treated with hemodialysis (HD).
- Trial name
- NCT00621426
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Cytomegalovirus Infections, HIV Infections
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes < 100 cells/mm3.
- Trial name
- NCT00001038
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 35 sites in United States, Australia and 8 more
- Volunteers
- 1,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Delayed Graft Function, Other Complication of Kidney Transplant
I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation
The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation.
- Trial name
- NCT00802347
- Testing
- I5NP, Saline
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 374 people
- Sponsor
- Quark Pharmaceuticals
Lung Cancer Squamous Cell, COPD
To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of inhaled corticosteroids combined with bronchodilators and programmed death-ligand 1 (PD-L1) inhibitor plus platinum-based chemotherapy in patients with advanced lung squamous cell carcinoma…
- Trial name
- NCT06772454
- Testing
- Antitumor therapy, Inhaled preparation for COPD
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
MPS II, Mucopolysaccharidosis II
MPS II Immunophenotyping
The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses…
- Conditions
- MPS II, Mucopolysaccharidosis II, Hunter Syndrome
- Trial name
- NCT04976231
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Rhabdomyolysis, Death
The Rhabdomyolysis Evaluation in the Emergency Department (REED) Score
One in three adults over 65 fall annually, with one in five remaining on the floor for greater than one hour, which is referred to as a long lie.
- Conditions
- Rhabdomyolysis, Death, Kidney Replacement Therapy, Fall Patients
- Trial name
- The REED Score (NCT07158554)
- Where
- United Kingdom
- Volunteers
- 1,161 people
- Sponsor
- University of Salford
Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease End Stage
Effects of a Comprehensive Health Coaching Program in Advanced Chronic Obstructive Pulmonary Disease.
Chronic obstructive pulmonary disease due to incurable and prevalence has increased steadily, chronic respiratory disease is considered hazardous to health and quality of life of the disease.
- Trial name
- NCT03398772
- Testing
- Comprehensive Health Coaching Program
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Medical University
Ischemic Stroke
China Antihypertensive Trial in Acute Ischemic Stroke
This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.
- Trial name
- CATIS (NCT01840072)
- Testing
- Active antihypertensive treatment
- Where
- China
- Volunteers
- 4,071 people
- Sponsor
- Tulane University
End of Life
Study of Poetic Dignity Therapy for Sexual and Gender Minority Patients With Cancer
The purpose of this study is to find out if dignity therapy is practical and works well for sexual and gender minority (SGM) patients in MSK.
- Trial name
- NCT06293456
- Testing
- Dignity Therapy
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Patient Transfer to Intensive Care Unit (Procedure), Respiratory Arrest (Disorder)
Evaluation of the Patient Deterioration Warning System
The overall goal of the project is to reduce the number of unexpected patient deteriorations by 50% at Emergency Departments (ED) by investigating if the novel Patient Deterioration Warning Systems (PDWS), can improve clinicians'…
- Conditions
- Patient Transfer to Intensive Care Unit (Procedure), Respiratory Arrest (Disorder), Cardiac Arrest (Disorder), Patient Died in Hospital (Finding)
- Trial name
- PDWS (NCT03375658)
- Testing
- PDWS Intervension
- Where
- 2 sites in Denmark
- Volunteers
- 6,500 people
- Sponsor
- University of Southern Denmark
Non-squamous Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally…
- Trial name
- NCT06627647
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 301 sites in United States, Argentina and 23 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This is a phase 2, single-centre, randomized, multi-cohort trial of subjects with advanced Mismatch Repair Proficient Colorectal Cancer (MMRp-CRC), Pancreatic Adenocarcinoma (PA), and Leiomyosarcoma (LMS).
- Conditions
- Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
- Trial name
- DAPPER (NCT03851614)
- Testing
- Durvalumab, Olaparib, Cediranib
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
End of Life, Interdisciplinary Communication
Coaching Doctors in Ethical Decision-making (CODE)
Over the last few decades the fast technical and medical progress poses a significant challenge to doctors, who are asked to find the right balance between life-prolonging and palliative care.
- Conditions
- End of Life, Interdisciplinary Communication, Leadership
- Trial name
- CODE (NCT05167019)
- Testing
- CODE intervention, Usual care
- Where
- Belgium
- Volunteers
- 125 people
- Sponsor
- University Hospital, Ghent
Chronic Obstructive Airway Disease
Effect of Prolonged Decubitus on Nitric Oxide Concentration in Chronic Obstructive Pulmonary Disease
Bronchial obstruction in Chronic Obstructive Pulmonary Disease (COPD) is caused by inflammation of peripheral airways walls. Neutrophils and other inflammatory mediators Interleukin-6 (IL6), Interleukin-8 (IL8), Interleukin-1…
- Trial name
- NCT01555593
- Testing
- Cardioline Exp'air by Medi-soft - Sorinnes (B)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milan
The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.
Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer.
- Conditions
- The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to, Prophylaxis Given for 8±2 Days After Planned Laparoscopic, Surgery for Colorectal Cancer.
- Trial name
- PRO-LAPS I (NCT01589146)
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Of Perugia